NCT02346032View on ClinicalTrials.gov

Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

October 13, 2016

Conditions
Biliary Tract Cancer
Interventions
DRUG

refametinib

Refametinib will be administered orally at the starting dose of 50 mg twice daily on a continuous daily dosing schedule.

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT02346032 - Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma | Biotech Hunter | Biotech Hunter